AssetMark Inc
PGNX

AssetMark Inc’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

AssetMark Inc’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-222
Closed -$1K – 2178
2017
Q4 		$1K Buy
222
+22
+11% +$134 ﹤0.01% 1794
2017
Q3 		$1K Buy
+200
New +$1.27K ﹤0.01% 1440

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

AssetMark Inc's PGNX Position: Q1 2018 in Review

AssetMark Inc sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2018, closing a stake of 222 shares — an estimated $1K sold.

AssetMark Inc first reported a position in PGNX in Q3 2017 and held it in 2 quarters. The position peaked at $1K in Q4 2017. 152 funds tracked by Wall St. Rank hold PGNX as of Q1 2018.

  • AssetMark Inc reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • AssetMark Inc sold 222 Progenics Pharmaceuticals Inc shares in Q1 2018, an estimated $1K.
  • AssetMark Inc first reported a position in Progenics Pharmaceuticals Inc in Q3 2017 and held it in 2 quarters.
  • AssetMark Inc's Progenics Pharmaceuticals Inc position peaked at $1K in Q4 2017.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2018.

Based on AssetMark Inc's 13F filing for Q1 2018, filed 16 May 2018.